Pepkon Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Early Stage VC
- Investors
-
8
Pepkon General Information
Description
Developer of peptide-based therapeutic candidates in oncology designed to target cancer cell pathways and address the limitations of existing treatments for refractory cancers. The company offers in-house peptide design, chemical optimization, synthesis, and biological testing of drug candidates targeting the TSP-1/CD47 immune checkpoint pathway, enabling oncology researchers and clinical institutions to advance novel cancer immunotherapies.
Contact Information
Website
www.pepkon.frCorporate Office
- 19 chemin de Prunay
- 78430 Louveciennes
- France
Corporate Office
- 19 chemin de Prunay
- 78430 Louveciennes
- France
Pepkon Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Early Stage VC | 01-Aug-2024 | Completed | Generating Revenue | |||
| 5. Accelerator/Incubator | 20-May-2024 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 01-Jan-2024 | Completed | Pre-Clinical Trials | |||
| 3. Accelerator/Incubator | 05-Feb-2023 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | 01-Jan-2023 | Completed | Pre-Clinical Trials | |||
| 1. Accelerator/Incubator | 01-Jan-2022 | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Pepkon Patents
Pepkon Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11759496-B2 | Compounds and pharmaceutical use thereof in the treatment of cancer | Active | 10-May-2016 | ||
| US-20230414702-A1 | Compounds and pharmaceutical use thereof in the treatment of cancer | Inactive | 10-May-2016 | ||
| US-20190144501-A1 | New compounds and pharmaceutical use thereof in the treatment of cancer | Active | 10-May-2016 | ||
| EP-3434276-A1 | Method and pharmaceutical composition for use in the treatment of cancer | Active | 06-Jun-2012 | ||
| EP-3434276-B1 | Method and pharmaceutical composition for use in the treatment of cancer | Active | 06-Jun-2012 | C07K14/78 |
Pepkon Signals
Pepkon Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aloe Private Equity | PE/Buyout | Minority | ||
| Angel (individual) | Minority | |||
| Matwin | Accelerator/Incubator | |||
| Paris-Saclay Cancer Cluster | Accelerator/Incubator | |||
| JML Invest | Family Office | Minority |
Pepkon FAQs
-
When was Pepkon founded?
Pepkon was founded in 2022.
-
Where is Pepkon headquartered?
Pepkon is headquartered in Louveciennes, France.
-
What is the size of Pepkon?
Pepkon has 10 total employees.
-
What industry is Pepkon in?
Pepkon’s primary industry is Drug Discovery.
-
Is Pepkon a private or public company?
Pepkon is a Private company.
-
What is Pepkon’s current revenue?
The current revenue for Pepkon is .
-
Who are Pepkon’s investors?
Aloe Private Equity, , Matwin, Paris-Saclay Cancer Cluster, and JML Invest are 5 of 8 investors who have invested in Pepkon.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process